Gilgamesh Pharmaceuticals
YC S20New York City, US · Founded 2019 · 15 employees · 2 known investors
Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management. The company's pipeline spans depression, anxiety, addiction, and schizophrenia, with programs validated by AbbVie's acquisition of its first asset and partnerships with Columbia University and the National Institute on Drug Abuse.
AI & Machine LearningBiotechDigital HealthHealthtechTherapeuticsPsychedelicsMental Healthin /gilgamesh-pharmaceuticals/@GilgameshRX
Founders & leadership· Y Combinator alumni (S20)
Investors · 2
In the news
- Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal | 1470 & 100.3 WMBDwmbdradio.com · 2026
- Fierce Biotech Fundraising Tracker '26: AdvanCell adds $315M; Draig draws down $65Mfiercebiotech.com · 2026
- Sell or Invest in Gilgamesh Pharma Stock Pre-IPOnasdaqprivatemarket.com · 2026
- Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapiesprnewswire.com · 2026
- AbbVie inks $1.2B deal to buy Gilgamesh's psychedelic programfiercebiotech.com · 2025
- Gilgamesh raises funds to advance treatments for mental healthpharmaceutical-business-review.com · 2022
- Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatmentsprnewswire.com · 2022
- The Y Combinator Startup Raising Millions to Develop a New Psychedelic Drugsbusinessinsider.com · 2022